Published • loading... • Updated
Blood Test Outperforms Recommended Tools for Identifying Treatment-Eligible MASH Patients
Summary by Clinical Lab Products
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Blood Test Outperforms Recommended Tools for Identifying Treatment-Eligible MASH Patients
A cell-free DNA methylation test identified treatment-eligible patients more accurately than current clinical guidelines in a 528-patient study. Hepta, a liquid biopsy company, released clinical data showing its blood test identifies patients with metabolic dysfunction-associated steatohepatitis (MASH) eligible for treatment more accurately than the three non-invasive tests currently recommended by clinical guidelines. The study compared the per…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
